A5004407263- Inflammatory Bowel Disease
- Gut microbiota and health
- Gastrointestinal Bleeding Diagnosis and Treatment
- Esophageal and GI Pathology
- Gastroesophageal reflux and treatments
- Gastrointestinal disorders and treatments
- Clostridium difficile and Clostridium perfringens research
- Vitamin C and Antioxidants Research
- Microscopic Colitis
- Long-Term Effects of COVID-19
- Bariatric Surgery and Outcomes
- COVID-19 Clinical Research Studies
- Diet and metabolism studies
- Hydrogen's biological and therapeutic effects
- Dysphagia Assessment and Management
- Gastrointestinal motility and disorders
Valencian Infertility Institute
2024-2025
Hospital de Sagunto
2020-2025
Hospital Casa de Salud
2024
Hospital General Universitario De Valencia
2014-2016
Creative Research Enterprises (United States)
2016
Small intestinal bacterial overgrowth (SIBO) arises from dysbiosis in the small intestine, manifesting with abdominal symptoms. This study aims to assess efficacy of combined antibiotic therapy, herbal supplements, probiotics, and dietary modifications SIBO management. A total 179 SIBO-diagnosed patients underwent clinical evaluation breath testing. Patients were categorized into hydrogen (H2-SIBO) methane (CH4-SIBO) groups. The control group received standard therapy a low-FODMAP diet,...
Background: COVID-19 disease is a serious global health problem. Few treatments have been shown to reduce mortality and accelerate time recovery. The aim of this study was evaluate the potential effect food supplement (probiotics, prebiotics, vitamin D, zinc selenium) in patients admitted with COVID-19. Methods: A prospective randomized non-blinded clinical trial conducted sample 162 hospitalized diagnosed recruited over eight months. All received standard treatment, but intervention group...
Background: Small intestinal bacterial overgrowth (SIBO) is a dysbiosis marked by an excessive proliferation of bacteria in the small intestine, resulting abdominal symptoms that significantly affect patients' quality life. Objectives: This study aims to evaluate impact comprehensive therapeutic approach improving life patients with SIBO. Methods: For this purpose, standardized questionnaires were used at baseline, 30 days and 90 days, including IBS-QOL (Irritable Bowel Syndrome Quality Life...
Intestinal dysbiosis is key in the onset and development of Crohn's disease (CD). We evaluated microbiota changes CD patients before after a six-month anti-TNF treatment, comparing these with healthy subjects. This prospective multicenter observational study involved 27 initiating treatment 16 individuals. Inflammatory activity was determined at baseline, 3 6 months, classifying into responders non-responders. Fecal analyzed by massive genomic sequencing thought 16S rRNA amplicon six months...
Background: Crohn's disease is believed to result from the interaction between genetic susceptibility, environmental factors and gut microbiota, leading an aberrant immune response. The objectives of this study are evaluate qualitative quantitative changes in microbiota patients with after six months anti-tumor-necrosis factor (anti-TNFα) (infliximab or adalimumab) treatment determine whether these lead recovery normal when compared a control group healthy subjects. In addition, we will...